Evidence map›Paper›PMID 41662220›Full record

ArticleJournal of chemical information and modeling2026

Large Language Model Agent for Modular Task Execution in Drug Discovery.

Janghoon Ock, Radheesh Sharma Meda, Srivathsan Badrinarayanan, Neha S Aluru, Achuth Chandrasekhar, Amir Barati Farimani

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Polymer-Agent: Large Language Model Agent for Polymer Design.Journal of chemical information and modeling · 2026
    Article
  2. Review
  3. [Application and progress of artificial intelligence agents in drug development].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Janghoon OckDepartment of Chemical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, United States.ORCID 0009-0000-0370-4212
Radheesh Sharma MedaDepartment of Chemical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, United States.
Srivathsan BadrinarayananDepartment of Chemical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, United States.ORCID 0009-0004-6517-3145
Neha S AluruSchool of Engineering Medicine, Texas A&M University, Houston, Texas 77030, United States.
Achuth ChandrasekharDepartment of Material Science and Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, United States.ORCID 0009-0006-7054-8153
Amir Barati FarimaniDepartment of Mechanical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, United States.ORCID 0000-0002-2952-8576

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a modular framework powered by large language models (LLMs) that automates and streamlines key tasks across the early stage computational drug discovery pipeline. By combining LLM reasoning with domain-specific tools, the framework performs biomedical data retrieval, literature-grounded question answering via retrieval-augmented generation, molecular generation, multiproperty prediction, property-aware molecular refinement, and 3D protein-ligand structure generation. The agent autonomously retrieves relevant biomolecular information, including FASTA sequences, SMILES representations, and literature, and answers mechanistic questions with improved contextual accuracy compared to standard LLMs. It then generates chemically diverse seed molecules and predicted 75 properties, including ADMET-related and general physicochemical descriptors, which guids iterative molecular refinement. Across two refinement rounds, the number of molecules with QED >0.6 increased from 34 to 55. The number of molecules satisfying empirical drug-likeness filters also rose; for example, compliance with the Ghose filter increased from 32 to 55 within a pool of 100 molecules. The framework also employed Boltz-2 to generate 3D protein-ligand complexes and provide rapid binding affinity estimates for candidate compounds. These results demonstrate that the approach effectively supports molecular screening, prioritization, and structure evaluation. Its modular design enables flexible integration of evolving tools and models, providing a scalable foundation for AI-assisted therapeutic discovery.

Indexed as

Drug DiscoveryLarge Language ModelsLigandsLigands

Identifiers

PMID41662220
PMCPMC12933718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.